Impact of Atogepant on Migraine-Specific QoL Among Individuals With Episodic Migraine and Preventive Treatment Failure

被引：0

作者：

Tassorelli, C. ^{[1
,2
]}

Gandhi, P. ^{[3
]}

Sacco, S. ^{[4
]}

Pozo-Rosich, P. ^{[5
,6
]}

Lanteri-Minet, M. ^{[7
,8
,9
]}

Nezadal, T. ^{[10
]}

Trugman, J.

Luo, L. ^{[3
]}

Stokes, J. ^{[3
]}

Nagy, K. ^{[11
]}

机构：

[1] C Mondino Fdn, Headache Sci Ctr, Pavia, Italy

[2] Univ Pavia, Pavia, Italy

[3] AbbVie, Madison, NJ USA

[4] Carolinas Headache Clin, Matthews, NC USA

[5] Vall DHebron Univ Hosp, Barcelona, Spain

[6] Univ Autonoma Barcelona, Barcelona, Spain

[7] CHU Nice, Pain Dept, Nice, France

[8] CHU Nice, FHU InovPain, Nice, France

[9] Cote Azur Univ, Nice, France

[10] Charles Univ Prague, Mil Univ Hosp, Sch Med 1, Dept Neurol, Prague, Czech Republic

[11] AbbVie, Budapest, Hungary

来源：

EUROPEAN JOURNAL OF NEUROLOGY | 2023年 / 30卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

EPR-139

引用

页码：214 / 215

页数：2

共 50 条

[1] Effect of Atogepant on Headache Impact Test-6 Among Individuals With Episodic Migraine and Preventive Treatment Failure
Tassorelli, C.
Gandhi, P.
Sacco, S.
Pozo-Rosich, P.
Lanteri-Minet, M.
Nezadal, T.
Trugman, J.
Luo, L.
Stokes, J.
Nagy, K.
[J]. EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 : 215 - 216
[2] Atogepant for the Preventive Treatment of Migraine Among Participants With Episodic Migraine With Prior Treatment Failure: Results From the ELEVATE Trial
Pozo-Rosich, P.
Nagy, K.
Tassorelli, C.
Lanteri-Minet, M.
Sacco, S.
Nezadal, T.
Finnegan, M.
Guo, H.
Ferreira, De Abreu R.
Trugman, J.
[J]. HEADACHE, 2023, 63 : 117 - 117
[3] Atogepant for the Preventive Treatment of Migraine Among Participants With Episodic Migraine With Prior Treatment Failure: Results From the ELEVATE Trial
Pozo-Rosich, Patricia
Nagy, Krisztian
Tassorelli, Cristina
Lanteri-Minet, Michel
Sacco, Sara
Nezadal, Tomas
Finnegan, Michelle
Guo, Hua
Ferreira, Rosa De Abreu
Trugman, Joel M.
[J]. CEPHALALGIA, 2023, 43 (1supp) : 47 - 49
[4] Atogepant for the Preventive Treatment of Migraine
Ailani, Jessica
Lipton, Richard B.
Goadsby, Peter J.
Guo, Hua
Miceli, Rosa
Severt, Lawrence
Finnegan, Michelle
Trugman, Joel M.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (08): : 695 - 706
[5] The Impact of Fremanezumab on Migraine-Specific Health-Related Quality of Life in Episodic Migraine
Lipton, R. B.
Gandhi, S. K.
Fitzgerald, T.
Yeung, P. P.
Cohen, J. M.
Ma, Y.
Aycardi, E.
[J]. HEADACHE, 2018, 58 : 129 - 129
[6] The Impact of Fremanezumab on Migraine-Specific Health-Related Quality of Life in Episodic Migraine
Lipton, Richard B.
Gandhi, Sanjay K.
Fitzgerald, Timothy
Yeung, Paul P.
Cohen, Joshua M.
Ma, Yuju
Aycardi, Ernesto
[J]. JOURNAL OF HEADACHE AND PAIN, 2017, 18
[7] The Impact of Fremanezumab on Migraine-Specific Health-Related Quality of Life in Episodic Migraine
Lipton, Richard B.
Gandhi, Sanjay K.
Fitzgerald, Timothy
Yeung, Paul P.
Cohen, Joshua M.
Ma, Yuju
Aycardi, Ernesto
[J]. NEUROLOGY, 2018, 90
[8] Atogepant Improved Patient-Reported Migraine-Specific Quality of Life in a 12-Week Phase 3 (ADVANCE) Trial for Preventive Treatment of Migraine
Lipton, R. B.
Pozo-Rosich, P.
Blumenfeld, A. M.
Li, Y.
Severt, L.
Stokes, J.
Gandhi, P.
Dodick, D. W.
[J]. JOURNAL OF HEADACHE AND PAIN, 2021, 22 (SUPPL 1): : 106 - 107
[9] Atogepant improved patient-reported migraine-specific quality of life in a 12-week phase 3 (ADVANCE) trial for preventive treatment of migraine
Lipton, R. B.
Pozo-Rosich, P.
Blumenfeld, A. M.
Li, Y.
Severt, L.
Stokes, J.
Gandhi, P.
Dodick, D. W.
[J]. HEADACHE, 2021, 61 : 43 - 44
[10] Atogepant Improved Patient-Reported Migraine-Specific Quality of Life in a 12-Week Phase 3 (ADVANCE) Trial for Preventive Treatment of Migraine
Lipton, R. B.
Pozo-Rosich, P.
Blumenfeld, A. M.
Li, Y.
Severt, L.
Stokes, J.
Gandhi, P.
Dodick, D. W.
[J]. CEPHALALGIA, 2021, 41 (1_SUPPL) : 158 - 159

← 1 2 3 4 5 →